PLx Pharma Inc. to Present Virtually at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
The presentation will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the Company’s website at www.plxpharma.com, under the ‘Investors Relations’ Section.
VAZALORE 325 mg is an FDA-approved liquid-filled aspirin capsule that provides patients with vascular disease and diabetic patients who are candidates for aspirin therapy with faster, reliable and more predictable platelet inhibition as compared to enteric-coated aspirin, while also reducing the risk of stomach erosions and ulcers, as compared to immediate-release aspirin, common in an acute setting. PLx is focused on collecting the data, including results from a bioequivalence study, required for post-approval manufacturing changes, which will be included in the sNDA filing for VAZALORE 325 mg and to support approval of low dose VAZALORE 81 mg.
About PLx Pharma Inc.
To learn more about PLx Pharma Inc. and its pipeline, please visit www.plxpharma.com.
Source: PLx Pharma Inc.